Dec 2, 2025 · Data being presented showcases AbbVie's breadth and depth of research across a range of therapeutic modalities such as T-Cell Engagers, BCL-2 Inhibitors and Antibody-Drug …

1 day ago · AbbVie has delivered strong YTD outperformance, with shares up nearly 30% and robust analyst optimism, but I maintain a 'Hold' rating.

5 days ago · AbbVie is focusing on early-stage assets and gene therapy for retinal diseases to address unmet needs in wet AMD and DR. The acquisition of ImmunoGen and Cerevel …

Sep 11, 2025 · (Reuters) -AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq …

Dec 2, 2025 · AbbVie (NYSE: ABBV) today announced primary results from the pivotal Phase 3 ECLIPSE study, evaluating the safety, efficacy and tolerability of...

Dec 19, 2025 · The latest international Abbvie Inc news and views from Reuters - one of the world's largest news agencies

3 days ago · What's going on at AbbVie (NYSE:ABBV)? Read today's ABBV news from trusted media outlets at MarketBeat.

Jul 31, 2025 · AbbVie is raising its 2025 earnings guidance for the second time this year on the strength of the performance of the key drugs in its pipeline, despite a hit to earnings per share …

NewsNow aims to be the world's most accurate and comprehensive aggregator of AbbVie news, covering the latest share price, company announcements, vaccine trials, product news and …

Get the latest AbbVie Inc. (ABBV) stock news and headlines to help you in your trading and investing decisions.